HUE042196T2 - Vegyületek elhízás kezelésére és alkalmazási eljárásaik - Google Patents

Vegyületek elhízás kezelésére és alkalmazási eljárásaik

Info

Publication number
HUE042196T2
HUE042196T2 HUE14816018A HUE14816018A HUE042196T2 HU E042196 T2 HUE042196 T2 HU E042196T2 HU E14816018 A HUE14816018 A HU E14816018A HU E14816018 A HUE14816018 A HU E14816018A HU E042196 T2 HUE042196 T2 HU E042196T2
Authority
HU
Hungary
Prior art keywords
obesity
compounds
treatment
application procedures
procedures
Prior art date
Application number
HUE14816018A
Other languages
English (en)
Hungarian (hu)
Inventor
Umut Ozcan
Original Assignee
Childrens Medical Ct Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Ct Corp filed Critical Childrens Medical Ct Corp
Publication of HUE042196T2 publication Critical patent/HUE042196T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2264Obesity-gene products, e.g. leptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE14816018A 2013-11-26 2014-11-25 Vegyületek elhízás kezelésére és alkalmazási eljárásaik HUE042196T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361908998P 2013-11-26 2013-11-26

Publications (1)

Publication Number Publication Date
HUE042196T2 true HUE042196T2 (hu) 2019-06-28

Family

ID=52134396

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14816018A HUE042196T2 (hu) 2013-11-26 2014-11-25 Vegyületek elhízás kezelésére és alkalmazási eljárásaik

Country Status (18)

Country Link
US (1) US20160375039A1 (enExample)
EP (1) EP3074033B1 (enExample)
JP (2) JP6672157B2 (enExample)
AU (2) AU2014354831B2 (enExample)
CA (1) CA2931826C (enExample)
CY (1) CY1122551T1 (enExample)
DK (1) DK3074033T3 (enExample)
ES (1) ES2709976T3 (enExample)
HR (1) HRP20190219T1 (enExample)
HU (1) HUE042196T2 (enExample)
LT (1) LT3074033T (enExample)
PL (1) PL3074033T3 (enExample)
PT (1) PT3074033T (enExample)
RS (1) RS58422B1 (enExample)
SI (1) SI3074033T1 (enExample)
SM (1) SMT201900064T1 (enExample)
TR (1) TR201901299T4 (enExample)
WO (1) WO2015081093A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153933A1 (en) * 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN106008657B (zh) * 2016-05-20 2017-11-21 天津中医药大学 苦蘵苦素i及提取方法及用途
IT201800005336A1 (it) * 2018-05-14 2019-11-14 Composizioni per uso nel trattamento dell’obesità
WO2021072139A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides
CN113599502A (zh) * 2021-07-22 2021-11-05 廖儒佳 一种醉茄素a和瘦素的组合物及其在制备预防和或治疗出血性脑卒中药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
WO1996040912A1 (en) 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
IL122718A0 (en) 1995-06-30 1998-08-16 Lilly Co Eli Methods for treating diabetes
EP0865294B1 (en) 1995-08-17 2004-02-18 Amgen Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
ES2217327T3 (es) 1995-11-22 2004-11-01 Amgen Inc., Proteina ob para aumentar la masa de tejido magro.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
WO1997038014A1 (en) 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
CA2258504A1 (en) * 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
JP2001501177A (ja) 1996-08-30 2001-01-30 アムジエン・インコーポレーテツド Obタンパク質受容体をアップレギュレートすることによりobタンパク質に対する個体の感受性を増加させる方法
BR9711513A (pt) 1996-09-20 1999-08-24 Hoechst Ag Uso de antagonistas de leptina para o tratamento de resistencia a insulina em diabete do tipo ii
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
EA004790B1 (ru) 1996-12-20 2004-08-26 Амген Инк. Композиции на основе слитого белка ов и способы их применения
ATE223229T1 (de) 1997-04-17 2002-09-15 Amgen Inc Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
TR199902980T2 (xx) 1997-06-06 2000-05-22 Smithkline Beecham P.L.C. Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�.
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
PT1107793E (pt) 1998-08-10 2005-02-28 Amgen Inc Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
AU6396999A (en) 1998-10-02 2000-04-26 Amgen, Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CA2359840C (en) 1999-02-12 2012-10-23 Amgen Inc. Glycosylated leptin compositions and related methods
PL214862B1 (pl) 2001-10-22 2013-09-30 Amgen Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
JP4585186B2 (ja) * 2003-07-31 2010-11-24 杏林製薬株式会社 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤
JP2009541423A (ja) * 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と5‐ht6レセプター親和性の化合物との組合せ
US20110230551A1 (en) * 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
WO2010053655A2 (en) * 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
US8598339B2 (en) * 2011-02-01 2013-12-03 University Of Kansas Withanolide isolated from Physalis longifolia and analogs and methods of use thereof

Also Published As

Publication number Publication date
JP6672157B2 (ja) 2020-03-25
EP3074033B1 (en) 2018-11-07
RS58422B1 (sr) 2019-04-30
AU2018200517A1 (en) 2018-02-15
ES2709976T3 (es) 2019-04-22
SI3074033T1 (sl) 2019-03-29
US20160375039A1 (en) 2016-12-29
LT3074033T (lt) 2019-02-25
DK3074033T3 (en) 2019-02-11
WO2015081093A1 (en) 2015-06-04
AU2014354831B2 (en) 2017-10-26
CY1122551T1 (el) 2021-01-27
CA2931826A1 (en) 2015-06-04
AU2014354831A1 (en) 2016-06-09
EP3074033A1 (en) 2016-10-05
PL3074033T3 (pl) 2019-08-30
JP2016537431A (ja) 2016-12-01
SMT201900064T1 (it) 2019-02-28
JP2020059744A (ja) 2020-04-16
HRP20190219T1 (hr) 2019-03-22
TR201901299T4 (tr) 2019-02-21
AU2018200517B2 (en) 2019-12-19
CA2931826C (en) 2021-11-16
PT3074033T (pt) 2019-02-08

Similar Documents

Publication Publication Date Title
IL258402B1 (en) Electroporation for obesity or diabetes treatment
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
HUE042709T2 (hu) Cukorbetegség és elhízás kezelésére alkalmazható dehidrobenzofurán vegyületek
EP3164406C0 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
IL243976B (en) kdm1a inhibitors for disease treatment
IL243485A0 (en) Methods for treating or preventing ophthalmological conditions
HUE055755T2 (hu) Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
HUE057734T2 (hu) Heterociklusos vegyületek és alkalmazásuk
HUE040111T2 (hu) Vegyületek és alkalmazási eljárásaik
HUE053410T2 (hu) Alkalmazási eljárás és alkalmazási berendezés
HUE045274T2 (hu) Eljárás helyettesített oxiránok és triazolok elõállítására
DK3021838T3 (da) Behandling af fedme
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
EP3193862C0 (en) TOPICAL COMPOSITION OF CANNABINOIDS FOR THE TREATMENT OF ARTHRITIS PAIN
EP3174475C0 (en) CATHETER DEVICES AND KITS
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
LT3007726T (lt) Tautopatijos gydymo būdai
HUE040496T2 (hu) Vegyületek elhízás kezelésére és alkalmazási eljárásaik
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte
HUE046397T2 (hu) Artemizinin vegyületek és gefirin agonisták gyógyászati alkalmazása
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
DK3231793T3 (da) Dihydropyromidin-2-on-forbindelser og medicinske anvendelser deraf
DK3041831T3 (da) Alfa-te-saltformer: sammensætninger og anvendelser til behandling af sygdom